ClinicalTrials.gg
RecruitingNCT06194747QuITT-SEUpdated Apr 1, 2026

Improving Status Epilepticus Treatment Times

An interventional study of Quality improvement bundle and Quality improvement bundle and local PDSA cycles with central support in Status Epilepticus, sponsored by Nationwide Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 30 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Nationwide Children's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
30 Days to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.

Planned enrollment
4th of 30
450 · median 35
Started
2024
with 1 other
No phase
9 of 41
2 open now
Primary completion
2027-03
later than 2 of 12 live
Registered
34th of 41
by date

Among the 41 studies in Status Epilepticus with a site in United States, this one is the 4th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, reaches primary completion later than 2 of the 12 other live ones, and was the 34th registered.

Status Epilepticus

124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.

Browse Status Epilepticus studies →

Open to participants now

13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 30 Days to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Status Epilepticus with a site in United States, or all of them as a file.
02

Study summary

This is a stepped-wedge cluster randomized effectiveness-implementation hybrid study aimed at determining the effect of dissemination of a QI bundle on the time to treatment of SE among hospitalized, non-critically ill children. The primary study endpoint is to decrease the time from the SE diagnosis to treatment with the first dose of a benzodiazepine (BZD) as measured during hospitalization, which will decrease chances of morbidity and mortality.

Read the detailed description

The overall study design is a stepped-wedge cluster randomized trial. A stepped-wedge is a unidirectional crossover design in which clusters switch treatments at different time points, enabling statistically rigorous assessment of interventions while reducing ethical and resource limitations for quality improvement studies.[1] Seven centers will be randomly assigned to implement the QI bundle at staggered 1-month intervals after a baseline period. Only the timing of the dissemination visit will be randomized; all sites will receive the same materials and perform the same activities (e.g. focus group, process map development, simulations).

This study is an effectiveness-implementation hybrid study. The effectiveness-implementation hybrid design is ideal for assessing both clinical interventions and implementation.17 Importantly, our interventions have strong face-validity, are evidence-based, low-risk and low-cost. For instance, the price to change BZD formulations is nominal (\~$1 per dose), and other QI bundle interventions are primarily focused on frontline staff process changes. While testing the effect of the QI bundle on time to BZD treatment, we will utilize this framework and mixed methods analysis to measure implementation and identify barriers and facilitators. Thus, this proposal is of high-value, as it will provide randomized multicenter efficacy data while providing understanding for broad implementation following study end.

For the effectiveness component, we will utilize a stepped-wedge cluster randomized design. Based on our preliminary data, the intraclass correlation coefficient is estimated around 0.5, an overall sample size of 60 episodes will be adequate to achieve powers greater than 90%. A potential pitfall of the stepped wedge design is the potential confounding effects of temporal trends. We will mitigate this by tracking data at the primary site, which will be in the sustain phase throughout the study entirety. We reduce temporal effects of site enrollment (e.g., staffing changes, temporal trends in hospital admissions) by enrolling sites at different times throughout the calendar year.

The implementation component was designed utilizing the Practical, Robust Implementation and Sustainability Model (PRISM).[2] PRISM provides a scientifically rigorous and structured approach to implementation strategy development through domains focusing on (1) program, (2) external environment, (3) implementation and sustainability infrastructure and (4) recipients.[2] These elements are addressed as follows:

Program. Organizational readiness across the study sites will be critical for success. Our proposal is based on evidence derived from a successful single-center study. The QI bundle is low-cost and all interventions are currently FDA-approved. Our innovative de-implementation of time-consuming, low-value workflows (e.g. IV medication administration) will decrease care complexity in the initial stages of SE treatment. The QI bundle components are trialable, adaptable and reversible. Treatment results are immediately observable by stakeholders through individual outcomes (SE cessation) and shared measure and feedback data reports. We highlight improved outcomes and safety as organizational, caregiver, and patient priorities to achieve broad buy-in.

External Environment. Regulatory and professional organization priorities support our area of study and primary efficacy outcomes. Rapid treatment of SE has been identified as a quality measure by the AAN11, and guidelines for such care have been published by the AES.[3] Additionally, our study proposal further aligns with NAEC, which mandates a focus on rapid treatment of SE through pathway requirements across 260 hospitals. Data from our proposal will serve as a framework for accomplishing the goal of rapid SE treatment, which is inconsistently met at present.[4]

Implementation and sustainability infrastructure. Our infrastructure will utilize proven features associated with successful implementation projects.[5,6] Co-investigators experienced in working within pSERG will provide a bridge to the local QI and clinical teams, engaging stakeholders at all 3 organizational levels (frontline staff, mid-level management and senior administration). Measure and feedback will be emphasized through control chart data and implementation reports. Furthermore, the adaptable protocol allows for site-specific implementation strategies for the QI bundle as well as iterative PDSA development in the Sustain and Independent phases in order to address local drivers.

Recipients. Positive organizational characteristics are supported by LOS from senior hospital administrators and nurse managers. Furthermore, the co-investigators have previously collaborated with pSERG from their respective centers. Each site has access to data through Export, Transform, Load (ETL) data queries and EHR. The diverse demographics of patients is aided through intentional site selection and inclusion of nearly all ages of children. Importantly, our proposed interventions of performing basic seizure first aid and using non-IV forms of BZD aligns with those of patients and families in the ambulatory setting.[7]

03

Conditions studied

  • Status Epilepticus

Browse trials for

Keywords

  • Status Epilepticus
  • Quality Improvement
  • Interventions
04

Who can participate

Ages eligible
30 Days to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SE episode occurs in a male or female child aged between > 30 days to \< 19 years
  • Seizures meeting AT LEAST ONE of the following criteria:

    1. continuous clinically apparent seizure lasting greater than 5 minutes
    2. continuous clinically apparent seizure of any duration receiving BZD
    3. repeated seizures without return to neurological baseline within 5 minutes

Exclusion criteria

Exclusion Criteria:

  • SE episode occurs in a child with infantile spasms
  • SE episode occurs in a child with electrographic-only seizures without clinical signs other than encephalopathy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
450 participants (estimated)

Study arms

  • No intervention
    Baseline phase

    During this arm, sites will provide routine care.

  • Experimental
    Adoption phase

    Following the dissemination visit, sites will actively work to implement the bundle of interventions.

    Other: Quality improvement bundle

  • Experimental
    Sustain phase

    During this arm, sites will actively work to sustain the implemented interventions and will be allowed to develop site-specific plan-do-study-act cycles in order to address site-specific key drivers with central data and methodological support.

    Other: Quality improvement bundle and local PDSA cycles with central support

  • Experimental
    Independent phase

    During this arm, sites will continue to sustain the implemented interventions and develop site-specific plan-do-study-act cycles in order to address site-specific key drivers without central data and methodological support.

    Other: Quality improvement bundle and local PDSA cycles without central support

Interventions

  • OtherQuality improvement bundle

    (1) standardizing BZD default to intranasal or buccal midazolam; (2) targeting initial BZD treatment within 10 minutes of seizure onset; (3) relocating and bundling all administration items needed to the hospital unit medication room; (4) utilizing basic seizure first aid in the initial patient assessment; (5) developing and implementing SE-specific EHR documentation; (6) multidisciplinary QI teams

  • OtherQuality improvement bundle and local PDSA cycles with central support

    Sites will implement both the standard QI bundle as well as site-specific PDSA cycles with central data and methods support.

  • OtherQuality improvement bundle and local PDSA cycles without central support

    Sites will implement both the standard QI bundle as well as site-specific PDSA cycles without central data or methods support.

06

What researchers measure

Primary outcomes

  1. Time from the SE diagnosis to first dose of BZD

    Time in minutes from SE diagnosis to treatment with the first dose of a benzodiazepine (BZD) as measured during hospitalization, which will decrease chances of morbidity and mortality

    Time frame: 30 days

Secondary outcomes

  1. ICU transfer rate

    Percent of SE episodes resulting in transfer to the ICU within 6 hours of the episode as well as at any point during the admission.

    Time frame: 30 days

  2. Cost of hospitalization

    Cost of hospitalization will be calculated as follows: cost per SE type x LOS

    Time frame: 30 days

  3. Change in PCPC score

    Change in PCPC score from admission to discharge

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007 Feb;28(2):182-91. doi: 10.1016/j.cct.2006.05.007. Epub 2006 Jul 7. PubMed 16829207 ↗
  • Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Jt Comm J Qual Patient Saf. 2008 Apr;34(4):228-43. doi: 10.1016/s1553-7250(08)34030-6. PubMed 18468362 ↗
  • Solberg LI, Brekke ML, Fazio CJ, Fowles J, Jacobsen DN, Kottke TE, Mosser G, O'Connor PJ, Ohnsorg KA, Rolnick SJ. Lessons from experienced guideline implementers: attend to many factors and use multiple strategies. Jt Comm J Qual Improv. 2000 Apr;26(4):171-88. doi: 10.1016/s1070-3241(00)26013-6. PubMed 10749003 ↗
  • Bradley EH, Holmboe ES, Mattera JA, Roumanis SA, Radford MJ, Krumholz HM. A qualitative study of increasing beta-blocker use after myocardial infarction: Why do some hospitals succeed? JAMA. 2001 May 23-30;285(20):2604-11. doi: 10.1001/jama.285.20.2604. PubMed 11368734 ↗
  • O'Hara KA. First aid for seizures: the importance of education and appropriate response. J Child Neurol. 2007 May;22(5 Suppl):30S-7S. doi: 10.1177/0883073807303066. PubMed 17690085 ↗
  • Ostendorf AP, Loddenkemper T, Morgan LA, Appavu B, Farias-Moeller R, Harrar D, Press C, Abend NS, Gaillard WD, Bai S, Eisner M, McHenry L, Kroshus E, Vannatta K, Goodkin HP. Treating seizures faster: The Quality Improvement in Time to Treat Status Epilepticus (QuITT-SE) multicenter randomized stepped wedge clinical trial protocol. Contemp Clin Trials. 2025 Apr;151:107831. doi: 10.1016/j.cct.2025.107831. Epub 2025 Feb 8. PubMed 39929261 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Mar 2027, 37 months after the start.

Of 22 interventional studies with no phase under Status Epilepticus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 65. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2023
First posted
Jan 8, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06194747
Collaborators
Children's Hospital of Philadelphia, Boston Children's Hospital, Children's National Research Institute, Children's Hospital and Health System Foundation, Wisconsin, UVA Children's Hospital, Seattle Children's Hospital, Phoenix Children's Hospital, Emory University
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Feb 1, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Adam Ostendorf, MD
Contact
adam.ostendorf@nationwidechildrens.org
614-722-5145
Adam Ostendorf, MD
principal investigator · Nationwide Children's Hospital and The Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion